ENDRA Life Sciences (Nasdaq: NDRA)

Medical Equipment ManufacturingMichigan, United States11-50 Employees

ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI - at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD).  

ENDRA's goal is to bring new capabilities to ultrasound - thereby broadening access to better healthcare. For more information, please visit www.endrainc.com. 

Non-Alcoholic Fatty Liver Disease (NAFLD) is a condition closely associated with obesity, diabetes, hepatitis-C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S healthcare system over $100B annually.   NAFLD is often asymptomatic and, If left untreated, NAFLD can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer.   By 2025, NAFLD is forecast to be the greatest root cause of liver transplants.  The only tools currently available for diagnosing and monitoring NAFLD are impractical:  expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy.

Sign up for free to view info

Email Format Employee directory